Abstract Library

#3022 Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms

Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giannone F

Authors: Giannone F, Muffatti F, Partelli S, Andreasi V, Guarneri G,

Keywords: imaging, lymph node, metastases,

#2278 Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?

Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Giannone F

Authors: Giannone F, Partelli S, Muffatti F, Balzano G, Crippa S,

Keywords: incidentaloma, microadenoma,

#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study

Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Partelli S

Authors: Partelli S, Kidd M, Muffatti F, Andreasi V, Giannone F,

Keywords: NETest, biomarker, Enteropancreatic Neuroendocrine Tumors, diagnosis, surgery,

#2200 Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent

Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Muffatti F

Authors: Muffatti F, Partelli S, Rancoita P, Andreasi V, Giannone F,

Keywords: NF-PanNET, tumor size, age, Ki-67,

#678 Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide

Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wolin E

Authors: Wolin E, Giannone V, Hermasillo Resendiz K,

Keywords: somatostatin analog, pasireotide, carcinoid syndrome,